Outlook for the next 5 years in drug innovation

Nature Reviews Drug Discovery

Volumn 11, Issue 6, 2012, Pages 435-436

  Berggren, Roy ^a   Møller, Martin ^a   Moss, Rachel ^a   Poda, Pawel ^a   Smietana, Katarzyna ^a  

^a MCKINSEY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER CHEMOTHERAPY; DRUG APPROVAL; DRUG COST; DRUG DESIGN; DRUG EFFICACY; DRUG INDUSTRY; DRUG MARKETING; DRUG PROGRAM; DRUG RESEARCH; DRUG SURVEILLANCE PROGRAM; DRUG USE; INVESTMENT; PRIORITY JOURNAL; PRODUCT DEVELOPMENT; SHORT SURVEY;

ANTINEOPLASTIC AGENTS; BIOLOGICAL AGENTS; DIFFUSION OF INNOVATION; DRUG DISCOVERY; DRUG INDUSTRY; ECONOMICS, PHARMACEUTICAL; HUMANS; SMALL MOLECULE LIBRARIES;

EID: 84861862727     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd3744     Document Type: Short Survey

References (2)

1. Paul, S. M. et al. How to improve R&D productivity: the pharmaceutical industry's grand challenge. Nature Rev. Drug Discov. 9, 203-215 (2010).
2. David, E., Tramontin, T. & Zemmel, R. Pharmaceutical R&D: the road to positive returns. Nature Rev. Drug Discov. 8, 609-610 (2009).